Stock ANEB ANEBULO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Anebulo Pharmaceuticals, Inc.

Equities

ANEB

US0345691036

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
3.12 USD +5.41% Intraday chart for Anebulo Pharmaceuticals, Inc. +11.65% +28.93%
Feb. 13 Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
2023 Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
BU
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
CI
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
BU
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
AQ
Anebulo Pharmaceuticals Announces New CEO
AQ
Anebulo Pharmaceuticals Appoints New CEO
MT
Anebulo Pharmaceuticals Announces New CEO
BU
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
BU
Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO
CI
Anebulo Pharmaceuticals, Inc. Appoints Bimal Shah to Its Board of Directors
CI
Anebulo Pharmaceuticals Appoints Daniel George as Part-Time Finance Chief
MT
Anebulo Pharmaceuticals, Inc. Announces Chief Financial Officer Changes
CI
Anebulo Pharmaceuticals, Inc. Appoints Daniel George as Principal Financial Officer and Principal Accounting Officer
CI
Maxim Starts Anebulo Pharmaceuticals at Buy With $6 Price Target
MT
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
BU
Anebulo Pharmaceuticals : Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates - Form 8-K
PU
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023
CI
Kronos Bio Appoints Sandra Gardiner as Interim Chief Financial Officer
MT
HC Wainwright Initiates Anebulo Pharmaceuticals With Buy Rating, Price Target is $6
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANEB Stock
  4. News Anebulo Pharmaceuticals, Inc.